(Q37738576)

22 August 2017

1 reference

title

Treatment of immunoglobulin light chain amyloidosis (English)

1 reference

22 August 2017

1

Morie A Gertz

1 reference

22 August 2017

2

Steven R Zeldenrust

1 reference

22 August 2017

1 April 2009

1 reference

Current hematologic malignancy reports

22 August 2017

1 reference

22 August 2017

4

1 reference

22 August 2017

2

1 reference

22 August 2017

91-98

1 reference

https://scigraph.springernature.com/pub.10.1007/s11899-009-0013-6

22 August 2017

0 references

cites work

Clinical aspects of systemic amyloid diseases.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11899-009-0013-6

AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11899-009-0013-6

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11899-009-0013-6

Therapy of Primary Amyloidosis With Melphalan and Prednisone

21 January 2018

1 reference

12 December 2020

Therapeutic outcome of cyclic VAD (vincristine, doxorubicin and dexamethasone) therapy in primary systemic AL amyloidosis patients

1 reference

12 December 2020

Survival of patients with primary (AL) amyloidosis. Colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973)

1 reference

12 December 2020

AH amyloidosis associated with an immunoglobulin heavy chain variable region (VH1) fragment: a case report

1 reference

12 December 2020

Letter: Improvement in amyloidosis

1 reference

12 December 2020

The potential of proteasome inhibitors in cancer therapy

1 reference

12 December 2020

Severity of Baseline Proteinuria Predicts Renal Response in Immunoglobulin Light Chain-Associated Amyloidosis after Autologous Stem Cell Transplantation

1 reference

12 December 2020

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine

1 reference

12 December 2020

Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis

1 reference

12 December 2020

Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support.

1 reference

12 December 2020

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

1 reference

12 December 2020

Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis.

1 reference

12 December 2020

Azotemia associated with use of lenalidomide in plasma cell dyscrasias

1 reference

12 December 2020

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis

1 reference

12 December 2020

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

1 reference

12 December 2020

Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL)

1 reference

12 December 2020

Amyloidosis (AL). Clinical and laboratory features in 229 cases

1 reference

12 December 2020

Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response

1 reference

12 December 2020

High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant

1 reference

12 December 2020

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease

1 reference

12 December 2020

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

1 reference

12 December 2020

Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

1 reference

12 December 2020

Autologous stem cell transplantation for primary systemic amyloidosis

1 reference

12 December 2020

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy

1 reference

12 December 2020

Bortezomib in the treatment of AL amyloidosis: targeted therapy?

1 reference

12 December 2020

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

1 reference

12 December 2020

Aberrant immunoglobulin synthesis in light chain amyloidosis. Free light chain and light chain fragment production by human bone marrow cells in short-term tissue culture

1 reference

12 December 2020

Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis.

1 reference

12 December 2020

Transplantation for amyloidosis

1 reference

12 December 2020

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

1 reference

12 December 2020

Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628.

1 reference

12 December 2020

Monitoring the assembly of Ig light-chain amyloid fibrils by atomic force microscopy.

1 reference

12 December 2020

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

1 reference

12 December 2020

Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients.

1 reference

12 December 2020

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

1 reference

12 December 2020

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).

1 reference

12 December 2020

Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis

1 reference

12 December 2020

Pathogenesis and treatment of renal failure in multiple myeloma

1 reference

12 December 2020

Resolution of amyloidosis and plasma-cell dyscrasia with combination chemotherapy

1 reference

12 December 2020

Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation.

1 reference

12 December 2020

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone

1 reference

12 December 2020

Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation

1 reference

12 December 2020

High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study

1 reference

12 December 2020

Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis

1 reference

12 December 2020

Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide

1 reference

12 December 2020

Systemic immunoglobulin light-chain amyloidosis

1 reference

12 December 2020

Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma

1 reference

12 December 2020

Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma

1 reference

12 December 2020

Response rates and survival in primary systemic amyloidosis

1 reference

12 December 2020

Stem cell transplantation for the management of primary systemic amyloidosis

1 reference

12 December 2020

Treatment of AL-amyloidosis with dexamethasone plus alpha interferon

1 reference

12 December 2020

Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis.

1 reference

12 December 2020

Five or more years of survival in patients with primary systemic amyloidosis and biopsy-proven cardiac involvement

1 reference

12 December 2020

High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study

1 reference

12 December 2020

Long-term survival (10 years or more) in 30 patients with primary amyloidosis

1 reference

12 December 2020

A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis

1 reference

12 December 2020

Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients

1 reference

12 December 2020

Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies.

1 reference

12 December 2020

Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody

1 reference

12 December 2020

Outcome of autologous stem cell transplantation for AL amyloidosis in the UK

1 reference

12 December 2020

Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis

1 reference

12 December 2020

Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo

1 reference

12 December 2020

Effect of colchicine on experimental amyloidosis in two CBA/J mouse models. Chronic inflammatory stimulation and administration of amyloid-enhancing factor during acute inflammation

1 reference

12 December 2020

Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress.

1 reference

12 December 2020

High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis

1 reference

12 December 2020

Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate

1 reference

12 December 2020

The modulation of transthyretin tetramer stability by cysteine 10 adducts and the drug diflunisal. Direct analysis by fluorescence-detected analytical ultracentrifugation

1 reference

12 December 2020

Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis

1 reference

12 December 2020

Managing systemic light-chain amyloidosis

1 reference

12 December 2020

10.1007/S11899-009-0013-6

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20425420